CytomX Therapeutics Deploys Genedata Bioprocess
CytomX implements off-the-shelf Genedata workflow platform to accelerate development and manufacture of proprietary biotherapeutic modalities for cancer treatment
January 7, 2020
San Francisco, CA, USA
Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, has licensed Genedata Bioprocess® to act as an integrated workflow backbone for its bioprocess development operations. CytomX will use Genedata Bioprocess to streamline and automate its process development workflows and to make the development of next-generation production processes more efficient.
“As our portfolio of novel drug candidates continues to rapidly expand, we needed to ramp up our development operations to keep pace. Genedata Bioprocess ensures the upscaling of our new drug manufacturing processes,” said Sridhar Viswanathan, Ph.D., Senior Vice President, Process Sciences and Manufacturing Operations at CytomX Therapeutics. “Our decision to adopt the Genedata Bioprocess platform is based on its ability to directly integrate with our laboratory equipment and automate all data transfer, capture, processing, and data analysis and interpretation. By enabling true high-throughput processes, we can significantly reduce time, effort, and costs within our daily operations.”
Genedata Bioprocess has been implemented in CytomX’s process development groups, with a focus on managing and interpreting bioreactor online and offline data. In particular, the platform will be used for CytomX’s novel class of antibody therapeutics based on its Probody™ therapeutic technology platform. Genedata Bioprocess will be used across all R&D programs at CytomX, including both proprietary and partnered R&D programs.
End-to-end (E2E) Workflow Platform for Bioprocess Development & CMC
Co-developed over the last six years with major biopharmaceutical companies, Genedata Bioprocess has been adopted by large, multinational biopharmaceutical companies and CMOs, as well as by smaller, innovative biotechnology organizations. The platform integrates all data generated along the biopharmaceutical development and CMC process, including upstream (USP), downstream (DSP), and analytics functions. It enables fully-automated processes, such as streamlining highly parallelized scale-down expression experiments in ambr® mini-bioreactors and data processing for large-scale bioreactors. In addition, by providing a central platform, it accelerates and improves the drug candidate’s transition from research to development. Built on a modular and scalable architecture, the platform is suitable for installations ranging from single-site groups to global, multi-site biopharma development organizations.
“We are delighted that CytomX, a leader with an innovative oncology drug development platform, has implemented Genedata Bioprocess to streamline their biopharma development operations,” said Othmar Pfannes, Ph.D., CEO of Genedata. “We are pleased to see that our integrated R&D workflow platform helps our rapidly growing customer base to reduce R&D process complexity, thereby enabling a cost-efficient development of innovative drugs that will help patients worldwide.”
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.